On 19 February, at its plenary session in Berlin, the Gemeinsame Bundesausschuss (G-BA), Germany’s highest healthcare decision-making body representing physicians, dentists, hospitals and statutory health insurers, determined that the amyloid antibody lecanemab shows no evidence of added benefit in the treatment of early Alzheimer's disease (AD) compared with the current standard of care. Overall, the G-BA concluded that no advantages or disadvantages relevant to the benefit assessment could be identified for lecanemab compared to the current standard therapy. Consequently, the committee found that no additional benefit has been demonstrated.
Lecanemab has been available in Germany since September 2025 for people with mild cognitive impairment and mild dementia as part of the treatment of early AD. Under Germany’s pharmaceutical regulation system, the G-BA's decision now forms the basis for price negotiations for the drug between the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) and the drug’s manufacturer. The G-BA decision does not entail any new restrictions on prescribing lecanemab.
https://www.navlindaily.com/article/29585/g-ba-rules-no-added-benefit-for-alzheimer-s-drug-leqembi-in-germany
Read the G-BA’s announcement here: https://www.g-ba.de/presse/pressemitteilungen-meldungen/1313/
